Maarten E A Reith

List of Publications by Year in Descending Order

144 papers	5,212 citations	38 h-index	65 g-index
150 ext. papers	5,707 ext. citations	5.9 avg, IF	5.48 L-index

#	Paper	IF	Citations
144	Novel Potent Dopamine-Norepinephrine and Triple Reuptake Uptake Inhibitors Based on Asymmetric Pyran Template and Their Molecular Interactions with Monoamine Transporters. *ACS Chemical Neuroscience*, **2021**, 12, 1406-1418	5.7	1
143	SLC6 transporter oligomerization. *Journal of Neurochemistry*, **2021**, 157, 919-929	6	9
142	Molecular Mechanisms of Amphetamines. *Handbook of Experimental Pharmacology*, **2020**, 258, 265-297	3.2	11
141	D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats. *European Journal of Pharmacology*, **2019**, 862, 172632	5.3	3
140	Biased signaling agonist of dopamine D3 receptor induces receptor internalization independent of □arrestin recruitment. *Pharmacological Research*, **2019**, 143, 48-57	10.2	14
139	Selective activation of Dopamine D3 receptors and norepinephrine transporter blockade enhances sustained attention. *Neuropharmacology*, **2019**, 148, 178-188	5.5	8
138	Design, Synthesis, and Pharmacological Characterization of Carbazole Based Dopamine Agonists as Potential Symptomatic and Neuroprotective Therapeutic Agents for Parkinson□s Disease. *ACS Chemical Neuroscience*, **2019**, 10, 396-411	5.7	11
137	Latch and trigger role for R445 in DAT transport explains molecular basis of DTDS. *Bioorganic and Medicinal Chemistry Letters*, **2018**, 28, 470-475	2.9	1
136	Tamoxifen Directly Interacts with the Dopamine Transporter. *Journal of Pharmacology and Experimental Therapeutics*, **2018**, 367, 119-128	4.7	7
135	Functional properties of dopamine transporter oligomers after copper linking. *Journal of Neurochemistry*, **2018**, 144, 162-171	6	14
134	A Novel Iron(II) Preferring Dopamine Agonist Chelator as Potential Symptomatic and Neuroprotective Therapeutic Agent for Parkinson□s Disease. *ACS Chemical Neuroscience*, **2017**, 8, 723-730	5.7	27
133	Effects of diet and insulin on dopamine transporter activity and expression in rat caudate-putamen, nucleus accumbens, and midbrain. *Journal of Neurochemistry*, **2017**, 140, 728-740	6	33
132	Dopamine transporter phosphorylation site threonine 53 is stimulated by amphetamines and regulates dopamine transport, efflux, and cocaine analog binding. *Journal of Biological Chemistry*, **2017**, 292, 19066-19075	5.4	13
131	Functional Characterization of a Novel Series of Biased Signaling Dopamine D3 Receptor Agonists. *ACS Chemical Neuroscience*, **2017**, 8, 486-500	5.7	24
130	Novel multifunctional dopamine D/D receptors agonists with potential neuroprotection and anti-alpha synuclein protein aggregation properties. *Bioorganic and Medicinal Chemistry*, **2016**, 24, 5088-5102	3.4	15
129	Efficacy of Hybrid Tetrahydrobenzo[d]thiazole Based Aryl Piperazines D-264 and D-301 at D□and D□ Receptors. *Neurochemical Research*, **2016**, 41, 328-339	4.6	3
128	Impact of disruption of secondary binding site S2 on dopamine transporter function. *Journal of Neurochemistry*, **2016**, 138, 694-9	6	9

127	Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. *Drug and Alcohol Dependence*, **2015**, 147, 1-19	4.9	91
126	Use of radiolabeled antagonist assays for assessing agonism at D2 and D3 dopamine receptors: comparison with functional GTP□S assays. *Journal of Neuroscience Methods*, **2015**, 248, 7-15	3	8
125	Mutations in SLC12A5 in epilepsy of infancy with migrating focal seizures. *Nature Communications*, **2015**, 6, 8038	17.4	104
124	Insulin enhances striatal dopamine release by activating cholinergic interneurons and thereby signals reward. *Nature Communications*, **2015**, 6, 8543	17.4	153
123	Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinities. *Journal of Neurochemistry*, **2015**, 133, 167-73	6	29
122	Development of a Highly Potent D2/D3 Agonist and a Partial Agonist from Structure-Activity Relationship Study of N(6)-(2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N(6)-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine	8.3	32
121	Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template. *Bioorganic and Medicinal Chemistry*, **2015**, 23, 821-8	3.4	6
120	Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model. *Bioorganic and Medicinal Chemistry*,	3.4	13
119	Design, synthesis, and structure-activity relationship studies of a series of [4-(4-carboxamidobutyl)]-1-arylpiperazines: insights into structural features contributing to dopamine D3 versus D2 receptor subtype selectivity. *Journal of Medicinal Chemistry*, **2014**, 57, 7042-60	8.3	29
118	Multifunctional D2/D3 agonist D-520 with high in vivo efficacy: modulator of toxicity of alpha-synuclein aggregates. *ACS Chemical Neuroscience*, **2014**, 5, 700-17	5.7	19
117	Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule. *Journal of Medicinal Chemistry*, **2014**, 57, 1557-72	8.3	23
116	Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters. *PLoS ONE*, **2014**, 9, e113420	3.7	8
115	Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. *Brain*, **2014**, 137, 1107-19	11.2	103
114	Novel structure--function information on biogenic amine transporters revealed by site-directed mutagenesis and alkylation. *Neurochemical Research*, **2013**, 38, 1301-2	4.6	
113	Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 3164-74	3.4	5
112	Nonclassical pharmacology of the dopamine transporter: atypical inhibitors, allosteric modulators, and partial substrates. *Journal of Pharmacology and Experimental Therapeutics*, **2013**, 346, 2-10	4.7	77
111	Effect of Iboga alkaloids on □-opioid receptor-coupled G protein activation. *PLoS ONE*, **2013**, 8, e77262	3.7	25
110	Characterization of [□H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive. *Journal of Neuroscience Methods*, **2012**, 203, 19-27	3	8

109	Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants. *ChemMedChem*, **2012**, 7, 2093-100	3.7	8
108	Novel bivalent ligands for D2/D3 dopamine receptors: Significant co-operative gain in D2 affinity and potency. *ACS Medicinal Chemistry Letters*, **2012**, 3, 991-996	4.3	24
107	Ibogaine and the inhibition of acetylcholinesterase. *Journal of Ethnopharmacology*, **2012**, 139, 879-82	5	10
106	Importance of cholesterol in dopamine transporter function. *Journal of Neurochemistry*, **2012**, 123, 700-15	5	59
105	Structure-activity relationship study of N-[2-(4-(1H-Indol-5-yl)piperazin-1-yl)ethyl)-N-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine analogues: development of highly selective D3 dopamine receptor agonists along with a highly potent D2/D3 agonist and their pharmacological characterization. *Journal of Medicinal Chemistry*, [illegible]	8.3	37
104	Novel C-1 substituted cocaine analogs unlike cocaine or benztropine. *Journal of Pharmacology and Experimental Therapeutics*, **2012**, 343, 413-25	4.7	14
103	Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents. *Journal of Medicinal Chemistry*, **2011**, 54, 2924-32	8.3	13
102	The atypical stimulant and nootropic modafinil interacts with the dopamine transporter in a different manner than classical cocaine-like inhibitors. *PLoS ONE*, **2011**, 6, e25790	3.7	89
101	SKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter. *Journal of Neurochemistry*, **2011**, 118, 714-20	6	9
100	Clinical and molecular characterisation of hereditary dopamine transporter deficiency syndrome: an observational cohort and experimental study. *Lancet Neurology, The*, **2011**, 10, 54-62	24.1	142
99	Interaction of novel hybrid compounds with the D3 dopamine receptor: Site-directed mutagenesis and homology modeling studies. *Biochemical Pharmacology*, **2011**, 81, 157-63	6	24
98	Dopamine D2/D3 agonists with potent iron chelation, antioxidant and neuroprotective properties: potential implication in symptomatic and neuroprotective treatment of Parkinson's disease. *ChemMedChem*, **2011**, 6, 991-5	3.7	29
97	Bivalent phenethylamines as novel dopamine transporter inhibitors: evidence for multiple substrate-binding sites in a single transporter. *Journal of Neurochemistry*, **2010**, 112, 1605-18	6	32
96	Interrelation of dopamine transporter oligomerization and surface presence as studied with mutant transporter proteins and amphetamine. *Journal of Neurochemistry*, **2010**, 114, 873-85	6	22
95	Regulation of the dopamine transporter: aspects relevant to psychostimulant drugs of abuse. *Annals of the New York Academy of Sciences*, **2010**, 1187, 316-40	6.5	136
94	Development of (S)-N6-(2-(4-(isoquinolin-1-yl)piperazin-1-yl)ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]-thiazole-2,6-diamine and its analogue as a D3 receptor preferring agonist: potent in vivo activity in Parkinson's disease [illegible] *Journal of Medicinal Chemistry*, **2010**, 53, 1023-37	8.3	48
93	Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinson's disease. *Journal of Medicinal Chemistry*, **2010**, 53, 2114-25	8.3	52
92	Further delineation of hydrophobic binding sites in dopamine D(2)/D(3) receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol. *Bioorganic and Medicinal Chemistry*, **2010**, 18, 5661-74	3.4	12

91	Substrate and drug binding sites in LeuT. *Current Opinion in Structural Biology*, **2010**, 20, 415-22	8.1	33
90	The selective dopamine uptake inhibitor, D-84, suppresses cocaine self-administration, but does not occasion cocaine-like levels of generalization. *European Journal of Pharmacology*, **2010**, 648, 127-32	5.3	3
89	Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. *Journal of Neuroscience Methods*, **2010**, 188, 32-8	3	15
88	Synthesis and biological characterization of (3R,4R)-4-(2-(benzhydryloxy)ethyl)-1-((R)-2-hydroxy-2-phenylethyl)-piperidin-3-ol and its stereoisomers for activity toward monoamine transporters. *ChemMedChem*, **2009**, 4, 1075-85	3.7	9
87	Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. *Nature Structural and Molecular Biology*, **2009**, 16, 652-7	17.6	200
86	Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters. *Journal of Neurochemistry*, **2009**, 109, 981-94	6	22
85	Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 3923-33	3.4	18
84	Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. *Journal of Clinical Investigation*, **2009**, 119, 1595-603	15.9	138
83	Substrates dissociate dopamine transporter oligomers. *Journal of Neurochemistry*, **2008**, 105, 910-20	6	38
82	Interaction of cocaine-, benztropine-, and GBR12909-like compounds with wild-type and mutant human dopamine transporters: molecular features that differentially determine antagonist-binding properties. *Journal of Neurochemistry*, **2008**, 107, 928-40	6	51
81	D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action. *European Journal of Pharmacology*, **2008**, 589, 73-9	5.3	20
80	Structurally constrained hybrid derivatives containing octahydrobenzo[g or f]quinoline moieties for dopamine D2 and D3 receptors: binding characterization at D2/D3 receptors and elucidation of a pharmacophore model. *Journal of Medicinal Chemistry*, **2008**, 51, 7806-19	8.3	21
79	Bioisosteric heterocyclic versions of 7-{[2-(4-phenyl-piperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol: identification of highly potent and selective agonists for dopamine D3 receptor with potent in vivo activity. *Journal of Medicinal Chemistry*, **2008**, 51, 3995-10	8.3	43
78	Further structure-activity relationships study of hybrid 7-{[2-(4-phenylpiperazin-1-yl)ethyl]propylamino}-5,6,7,8-tetrahydronaphthalen-2-ol analogues: identification of a high-affinity D3-preferring agonist with potent in vivo activity with long duration of action. *Journal of Medicinal Chemistry*, **2008**, 51, 404-17	8.3	41
77	Three-dimensional quantitative structure-activity relationship (3D QSAR) and pharmacophore elucidation of tetrahydropyran derivatives as serotonin and norepinephrine transporter inhibitors. *Journal of Computer-Aided Molecular Design*, **2008**, 22, 1-17	4.2	13
76	Further structural optimization of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine and 1,4-diazabicyclo[3.3.1]nonane derivatives by introducing an exocyclic hydroxyl group: interaction with dopamine, serotonin, and norepinephrine transporters. *Bioorganic and Medicinal Chemistry*, **2008**, 16, 2769-78	3.4	7
75	Substrates and inhibitors display different sensitivity to expression level of the dopamine transporter in heterologously expressing cells. *Journal of Neurochemistry*, **2007**, 101, 377-88	6	34
74	LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. *Science*, **2007**, 317, 1390-3	33.3	281

73	Chronic food restriction and dopamine transporter function in rat striatum. *Brain Research*, **2006**, 1082, 98-101	3.7	46
72	Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: a proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters. *Journal of Medicinal Chemistry*, **2006**, 49, 4239-47	8.3	26
71	Design, synthesis, and preliminary SAR study of 3- and 6-side-chain-extended tetrahydro-pyran analogues of cis- and trans-(6-benzhydryl-tetrahydropyran-3-yl)-benzylamine. *Bioorganic and Medicinal Chemistry*, **2006**, 14, 3953-66	3.4	7
70	Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates. *Neuropharmacology*, **2005**, 49, 769-79	5.5	12
69	Discovery of novel trisubstituted asymmetric derivatives of (2S,4R,5R)-2-benzhydryl-5-benzylaminotetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. *Journal of Medicinal Chemistry*, **2005**, 48, 4962-71	8.3	28
68	Pharmacological profile of radioligand binding to the norepinephrine transporter: instances of poor indication of functional activity. *Journal of Neuroscience Methods*, **2005**, 143, 87-94	3	12
67	Aspartate 345 of the dopamine transporter is critical for conformational changes in substrate translocation and cocaine binding. *Journal of Biological Chemistry*, **2004**, 279, 5508-19	5.4	40
66	Mutation of Trp84 and Asp313 of the dopamine transporter reveals similar mode of binding interaction for GBR12909 and benztropine as opposed to cocaine. *Journal of Neurochemistry*, **2004**, 89, 853-64	6	65
65	Interaction between dopamine and its transporter: role of intracellular sodium ions and membrane potential. *Journal of Neurochemistry*, **2004**, 89, 750-65	6	28
64	Interaction between a hydroxypiperidine analogue of 4-(2-benzhydryloxy-ethyl)-1-(4-fluorobenzyl)piperidine and Aspartate 68 in the human dopamine transporter. *European Journal of Pharmacology*, **2004**, 506, 17-26	5.3	14
63	Structure-activity relationships for substrate recognition by the human dopamine transporter. *Biochemical Pharmacology*, **2004**, 67, 293-302	6	16
62	Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. *Pflugers Archiv European Journal of Physiology*, **2004**, 447, 519-31	4.6	313
61	Synthesis and biological characterization of novel hybrid 7-[[2-(4-phenyl-piperazin-1-yl)-ethyl]-propyl-amino]-5,6,7,8-tetrahydro-naphthalen-2-ol and their heterocyclic bioisosteric analogues for dopamine D2 and D3 receptors. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 4361-73	3.4	37
60	Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters. *Bioorganic and Medicinal Chemistry*, **2004**, 12, 6301-15	3.4	21
59	Further structurally constrained analogues of cis-(6-benzhydrylpiperidin-3-yl)benzylamine with elucidation of bioactive conformation: discovery of 1,4-diazabicyclo[3.3.1]nonane derivatives and evaluation of their biological properties for the monoamine transporters. *Journal of Medicinal Chemistry*, **2004**, 47, 5101-13	8.3	16
58	The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. *Journal of Biological Chemistry*, **2004**, 279, 21012-20	5.4	130
57	Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. *European Journal of Pharmacology*, **2003**, 478, 89-95	5.3	29
56	Dopamine transporter as target for drug development of cocaine dependence medications. *European Journal of Pharmacology*, **2003**, 479, 93-106	5.3	61

55	Na+ and the substrate permeation pathway in dopamine transporters. *European Journal of Pharmacology*, **2003**, 479, 213-21	5.3	14
54	Binding of cocaine-like radioligands to the dopamine transporter at 37 degrees C: effect of Na+ and substrates. *Journal of Neuroscience Methods*, **2003**, 131, 27-33	3	5
53	Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. *Bioorganic and Medicinal Chemistry Letters*, **2003**, 13, 1591-5	2.9	16
52	Na+ stimulates binding of dopamine to the dopamine transporter in cells but not in cell-free preparations. *Journal of Neurochemistry*, **2003**, 86, 678-86	6	14
51	Interaction of cis-(6-benzhydrylpiperidin-3-yl)benzylamine analogues with monoamine transporters: structure-activity relationship study of structurally constrained 3,6-disubstituted piperidine analogues of (2,2-diphenylethyl)-[1-(4-fluorobenzyl)piperidin-4-ylmethyl]amine. *Journal of Medicinal Chemistry*, **2003**, 46, 2205-15	8.3	27
50	High affinity hydroxypiperidine analogues of 4-(2-benzhydryloxyethyl)-1-(4-fluorobenzyl)piperidine for the dopamine transporter: stereospecific interactions in vitro and in vivo. *Journal of Medicinal Chemistry*, **2003**, 46, 1220-8	8.3	28
49	Substrate-induced trafficking of the dopamine transporter in heterologously expressing cells and in rat striatal synaptosomal preparations. *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 307, 729-36	4.7	98
48	Nitric oxide scavenger carboxy-PTIO potentiates the inhibition of dopamine uptake by nitric oxide donors. *European Journal of Pharmacology*, **2002**, 448, 27-30	5.3	17
47	Is Na(+) required for the binding of dopamine, amphetamine, tyramine, and octopamine to the human dopamine transporter?. *Naunyn-Schmiedebergs Archives of Pharmacology*, **2002**, 365, 303-11	3.4	24
46	A novel series of hybrid compounds derived by combining 2-aminotetralin and piperazine fragments: binding activity at D2 and D3 receptors. *Bioorganic and Medicinal Chemistry Letters*, **2002**, 12, 619-22	2.9	33
45	An analysis of the binding of cocaine analogues to the monoamine transporters using tensor decomposition 3-d QSAR. *Bioorganic and Medicinal Chemistry*, **2002**, 10, 1197-206	3.4	14
44	Cationic interactions at the human dopamine transporter reveal binding conformations for dopamine distinguishable from those for the cocaine analog 2 alpha-carbomethoxy-3 alpha-(4-fluorophenyl)tropane. *Journal of Neurochemistry*, **2002**, 81, 1383-93	6	21
43	Nitric oxide inhibits uptake of dopamine and N-methyl-4-phenylpyridinium (MPP+) but not release of MPP+ in rat C6 glioma cells expressing human dopamine transporter. *British Journal of Pharmacology*, **2002**, 137, 1155-62	8.6	12
42	Expansion of structure-activity studies of piperidine analogues of 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)piperazine (GBR 12935) compounds by altering substitutions in the N-benzyl moiety and behavioral pharmacology of selected molecules. *Journal of Medicinal Chemistry*, **2002**, 45, 654-62	8.3	17
41	Concurrent autoreceptor-mediated control of dopamine release and uptake during neurotransmission: an in vivo voltammetric study. *Journal of Neuroscience*, **2002**, 22, 6272-81	6.6	115
40	The role of conserved tryptophan and acidic residues in the human dopamine transporter as characterized by site-directed mutagenesis. *Journal of Neurochemistry*, **2001**, 77, 1116-27	6	66
39	Rational design and synthesis of novel 2,5-disubstituted cis- and trans-piperidine derivatives exhibiting differential activity for the dopamine transporter. *Bioorganic and Medicinal Chemistry Letters*, **2001**, 11, 2337-40	2.9	20
38	Synthesis and preliminary characterization of a high-affinity novel radioligand for the dopamine transporter. *Synapse*, **2001**, 39, 175-81	2.4	7

37	Design, synthesis, and characterization of a novel, 4-[2-(diphenylmethoxy)ethyl]-1-benzyl piperidine-based, dopamine transporter photoaffinity label. *Life Sciences*, **2001**, 68, 1839-49	6.8	10
36	Structure-activity relationship studies of 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives and their N-analogues: evaluation of O-and N-analogues and their binding to monoamine transporters. *Journal of Medicinal Chemistry*, **2001**, 44, 937-48	8.3	27
35	Dual incorporation of photoaffinity ligands on dopamine transporters implicates proximity of labeled domains. *Molecular Pharmacology*, **2001**, 59, 1157-64	4.3	31
34	Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. *Journal of Neuroscience*, **2001**, 21, 6338-47	6.6	98
33	Interaction of Na+, K+, and Cl- with the binding of amphetamine, octopamine, and tyramine to the human dopamine transporter. *Journal of Neurochemistry*, **2000**, 74, 1538-52	6	19
32	Modeling of the interaction of Na+ and K+ with the binding of dopamine and [3H]WIN 35,428 to the human dopamine transporter. *Journal of Neurochemistry*, **1999**, 72, 1095-109	6	21
31	Continuous cocaine treatment and monoamine transmission measured by microdialysis in the rat ventral tegmental area. *Addiction Biology*, **1998**, 3, 447-51	4.6	
30	Carbamazepine-induced release of serotonin from rat hippocampus in vitro. *Epilepsia*, **1998**, 39, 1054-63	6.4	49
29	Tolerance in the replacement of the benzhydrylic O atom in 4-[2-(diphenylmethoxy)ethyl]-1-benzylpiperidine derivatives by an N atom: development of new-generation potent and selective N-analogue molecules for the dopamine transporter. *Journal of Medicinal Chemistry*, **1998**, 41, 3293-7	8.3	21
28	Potent and selective ligands for the dopamine transporter (DAT): structure-activity relationship studies of novel 4-[2-(diphenylmethoxy)ethyl]-1-(3-phenylpropyl)piperidine analogues. *Journal of Medicinal Chemistry*, **1998**, 41, 699-705	8.3	31
27	Highly selective, novel analogs of 4-[2-(diphenylmethoxy)ethyl]- 1-benzylpiperidine for the dopamine transporter: effect of different aromatic substitutions on their affinity and selectivity. *Journal of Medicinal Chemistry*, **1997**, 40, 35-43	8.3	45
26	Modeling of the interaction of Na+ and K+ with the binding of the cocaine analogue 3beta-(4-[125I]iodophenyl)tropane-2beta-carboxylic acid isopropyl ester to the dopamine transporter. *Journal of Neurochemistry*, **1997**, 68, 1968-81	6	15
25	Cations affect [3H]mazindol and [3H]WIN 35,428 binding to the human dopamine transporter in a similar fashion. *Journal of Neurochemistry*, **1997**, 69, 1106-18	6	11
24	Role of Axonal and Somatodendritic Monoamine Transporters in Action of Uptake Blockers **1997**, 345-391		6
23	Extracellular dopamine, norepinephrine, and serotonin in the nucleus accumbens of freely moving rats during intracerebral dialysis with cocaine and other monoamine uptake blockers. *Journal of Neurochemistry*, **1996**, 66, 559-68	6	76
22	Structure-activity relationship studies of novel 4-[2-[bis(4-fluorophenyl)methoxy]ethyl]-1-(3-phenylpropyl)piperidine analogs: synthesis and biological evaluation at the dopamine and serotonin transporter sites. *Journal of Medicinal Chemistry*, **1996**, 39, 749-56	8.3	56
21	Amygdala kindling of forebrain seizures and the occurrence of brainstem seizures in genetically epilepsy-prone rats. *Epilepsia*, **1996**, 37, 188-97	6.4	42
20	Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. *Naunyn-Schmiedebergs Archives of Pharmacology*, **1996**, 354, 295-304	3.4	18

19	Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin. *Journal of Neurochemistry*, **1995**, 64, 1585-97	6	77
18	Effects of locally applied cocaine, lidocaine, and various uptake blockers on monoamine transmission in the ventral tegmental area of freely moving rats: a microdialysis study on monoamine interrelationships. *Journal of Neurochemistry*, **1994**, 63, 1701-13	6	86
17	O-526, a piperidine analog of GBR 12909, retains high affinity for the dopamine transporter in monkey caudate-putamen. *European Journal of Pharmacology*, **1994**, 267, 167-73		19
16	Facilitation of amygdala kindling development and kindled seizures by metaphit. *Epilepsia*, **1994**, 35, 927-32	6.4	6
15	Cationic and anionic requirements for the binding of 2 beta-carbomethoxy-3 beta-(4-fluorophenyl)[3H]tropane to the dopamine uptake carrier. *Journal of Neurochemistry*, **1993**, 61, 167-77	6	50
14	Dopamine releasing effect of phenylbiguanide in rat striatal slices. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1992**, 345, 666-72	3.4	31
13	Sertraline and cocaine-induced locomotion in mice. I. Acute studies. *Psychopharmacology*, **1991**, 103, 297-305	4.7	27
12	Sertraline and cocaine-induced locomotion in mice. II. Chronic studies. *Psychopharmacology*, **1991**, 103, 306-13	4.7	9
11	Carrier-mediated efflux of [3H]dopamine and [3H]1-methyl-4-phenylpyridine: effect of ascorbic acid. *Synapse*, **1991**, 7, 99-105	2.4	8
10	Oxidative metabolism of cocaine: comparison of brain and liver. *Experimental Biology and Medicine*, **1989**, 190, 7-13	3.7	16
9	Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. *Naunyn-Schmiedebergʼs Archives of Pharmacology*, **1989**, 340, 626-32	3.4	60
8	Long-term blockade of the dopamine uptake complex by metaphit, an isothiocyanate derivative of phencyclidine. *Synapse*, **1989**, 3, 239-45	2.4	7
7	Nicotine-induced changes in the metabolism of specific brain proteins. *Neurochemical Research*, **1987**, 12, 197-202	4.6	3
6	Binding sites for [3H]cocaine in mouse striatum and cerebral cortex have different dissociation kinetics. *Journal of Neurochemistry*, **1986**, 46, 309-12	6	38
5	Binding of [3H]imipramine to mouse cerebrocortical membranes and to glass fiber filters. *Journal of Neurochemistry*, **1986**, 46, 760-6	6	9
4	Similarities and differences between high-affinity binding sites for cocaine and imipramine in mouse cerebral cortex. *Journal of Neurochemistry*, **1984**, 43, 249-55	6	29
3	Binding of imipramine and cocaine to a model lipid membrane: comparison with binding to brain membranes. *Neurochemical Research*, **1984**, 9, 965-77	4.6	8
2	From First to Fourth Messengers in the Brain: An Overview3-23		2